公开(公告)号：US06645506B1

公开(公告)日：2003-11-11

申请号：US09383975

申请日：1999-08-26

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A61K39108

CPC分类号： A61Q19/00 ,  A01N63/00 ,  A61K8/73 ,  A61K8/925 ,  A61K8/99 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0046 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/36 ,  A61K35/74 ,  A61K35/742 ,  A61K45/06 ,  A61K47/44 ,  A61L15/36 ,  A61Q19/001 ,  Y02A50/473 ,  Y10S514/887 ,  A61K2300/00

摘要： The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions which are comprised, in part, of isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain. In addition, the present invention also discloses compositions, methods of treatment, and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, comprising an extracellular product of Pseudomonas lindbergii comprising a supernatant or filtrate of a culture of said Pseudomonas lindbergii strain.

摘要翻译： 本发明公开了衍生自分离的芽孢杆菌属物种，孢子或凝结芽孢杆菌的细胞外产物的组合物，其包含适于局部施用于哺乳动物皮肤或粘膜的所述凝结芽孢杆菌菌株的培养物的上清液或滤液， 用于抑制细菌，酵母，真菌，病毒及其组合的生长。 本发明还公开了通过局部施用治疗组合物来抑制细菌，酵母，真菌，病毒及其组合的生长的治疗方法和治疗系统，所述治疗组合物部分地由分离的芽孢杆菌属物种，孢子或 包含凝结芽孢杆菌菌株培养物的上清液或滤液的凝结芽孢杆菌的细胞外产物。 此外，本发明还公开了组合物，治疗方法和用于抑制细菌，酵母，真菌，病毒及其组合的生长的治疗系统，所述组合物包含嗜热假单胞菌（Pseudomonas lindbergii）的细胞外产物，其包含上清液或培养物的滤液 所述假丝酵母菌（Lseudomonas lindbergii）菌株。

公开(公告)号：US06461607B1

公开(公告)日：2002-10-08

申请号：US09370793

申请日：1999-08-05

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A01N6300

CPC分类号： A61K35/742 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/745 ,  A61K35/747 ,  A61K38/14 ,  A61K45/06 ,  C12R1/07 ,  Y02A50/469 ,  Y02A50/475

摘要： The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

摘要翻译： 本发明公开了在治疗组合物中利用益生菌的组合物和方法。 更具体地，本发明涉及利用一种或多种乳酸生产菌种，优选芽孢杆菌属菌种来控制胃肠道病原体，包括抗生素抗性胃肠道病原体及其相关疾病 通过降低定植率和抗生素抗性病原体定植的有害生理效应的严重程度。 此外，本发明涉及由乳酸生产菌和抗微生物剂如抗生素，抗真菌化合物，抗酵母化合物或抗病毒化合物组成的治疗化合物的利用。 本发明还公开了以下方法：（i）对抗微生物剂（例如抗生素，抗真菌剂，抗酵母）具有抗性或显着降低的益生菌，产酸乳酸菌株的选择性育种和分离 药剂和抗病毒剂）; 和（ii）通过使用具有或不具有伴随的抗生素施用的上述益生菌细菌菌株来治疗或预防细菌介导的胃肠道感染。 虽然主要关注于治疗胃肠道感染，但是本发明的治疗组合物也可以施用于口腔，阴道，视觉和类似的生理位置。

公开(公告)号：US08697055B2

公开(公告)日：2014-04-15

申请号：US13423852

申请日：2012-03-19

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A01N63/00

CPC分类号： A61K35/742 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/745 ,  A61K35/747 ,  A61K38/14 ,  A61K45/06 ,  C12R1/07 ,  Y02A50/469 ,  Y02A50/475

摘要： The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen.

摘要翻译： 本发明公开了在治疗组合物中利用益生菌的组合物和方法。 更具体地，本发明涉及利用一种或多种乳酸生产菌种，优选芽孢杆菌属菌种来控制胃肠道病原体，包括抗生素抗性胃肠道病原体及其相关疾病 通过降低定植率和抗生素抗性病原体定植的有害生理效应的严重程度。

公开(公告)号：US08343484B2

公开(公告)日：2013-01-01

申请号：US12365808

申请日：2009-02-04

申请人： Sean Farmer ,  Andrew Lefkowitz

发明人： Sean Farmer ,  Andrew Lefkowitz

IPC分类号： A61K35/74 ,  A61K35/66

CPC分类号： A61K35/742 ,  A23L33/10 ,  A23L33/125 ,  A23L33/135 ,  A23L33/175 ,  A23V2002/00 ,  A61K9/0053 ,  A61K35/744 ,  A61K38/465 ,  A61K38/47 ,  A61K45/06 ,  A61K2035/11 ,  A61K2300/00

摘要： The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.

摘要翻译： 本发明一般涉及消化疾病，特别涉及通过施用含有凝结芽孢杆菌细菌的组合物来增加碳水化合物吸收来治疗肠易激综合征的方法。

公开(公告)号：US07807151B2

公开(公告)日：2010-10-05

申请号：US12148965

申请日：2008-04-23

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A61K35/00 ,  A61K31/70 ,  A61K31/43 ,  A61K31/545 ,  A61K31/47

CPC分类号： A61K35/742 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/745 ,  A61K35/747 ,  A61K38/14 ,  A61K45/06 ,  C12R1/07 ,  Y02A50/469 ,  Y02A50/475

摘要： The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

公开(公告)号：US07708988B2

公开(公告)日：2010-05-04

申请号：US11305507

申请日：2005-12-16

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A01N63/00

CPC分类号： A61K35/742 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/745 ,  A61K35/747 ,  A61K38/14 ,  A61K45/06 ,  C12R1/07 ,  Y02A50/469 ,  Y02A50/475

摘要： The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

摘要翻译： 本发明公开了在治疗组合物中利用益生菌的组合物和方法。 更具体地，本发明涉及利用一种或多种乳酸生产菌种，优选芽孢杆菌属菌种来控制胃肠道病原体，包括抗生素抗性胃肠道病原体及其相关疾病 通过降低定植率和抗生素抗性病原体定植的有害生理效应的严重程度。 此外，本发明涉及由乳酸生产菌和抗微生物剂如抗生素，抗真菌化合物，抗酵母化合物或抗病毒化合物组成的治疗化合物的利用。 本发明还公开了以下方法：（i）对抗微生物剂（例如抗生素，抗真菌剂，抗酵母）具有抗性或显着降低的益生菌，产酸乳酸菌株的选择性育种和分离 药剂和抗病毒剂）; 和（ii）通过使用具有或不具有伴随的抗生素施用的上述益生菌细菌菌株来治疗或预防细菌介导的胃肠道感染。 虽然主要关注于治疗胃肠道感染，但是本发明的治疗组合物也可以施用于口腔，阴道，视觉和类似的生理位置。

公开(公告)号：US07541042B2

公开(公告)日：2009-06-02

申请号：US11152894

申请日：2005-06-14

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A61K31/74 ,  A61K35/00 ,  A61K39/00 ,  A61K39/38 ,  A61K39/07 ,  A61K35/12 ,  A61K35/66 ,  A61K35/68 ,  A61K35/74 ,  A61K35/76 ,  A01N63/00 ,  A01N25/34 ,  A01N25/08 ,  A01N63/02 ,  C12N1/12 ,  C12N1/20

CPC分类号： A61Q19/00 ,  A01N63/00 ,  A61K8/73 ,  A61K8/925 ,  A61K8/99 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0046 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/36 ,  A61K35/74 ,  A61K35/742 ,  A61K45/06 ,  A61K47/44 ,  A61L15/36 ,  A61Q19/001 ,  Y02A50/473 ,  Y10S514/887 ,  A61K2300/00

摘要： The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions which are comprised, in part, of isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain. In addition, the present invention also discloses compositions, methods of treatment, and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, comprising an extracellular product of Pseudomonas lindbergii comprising a supernatant or filtrate of a culture of said Pseudomonas lindbergii strain.

摘要翻译： 本发明公开了衍生自分离的芽孢杆菌属物种，孢子或凝结芽孢杆菌的细胞外产物的组合物，其包含适于局部施用于哺乳动物皮肤或粘膜的所述凝结芽孢杆菌菌株的培养物的上清液或滤液， 用于抑制细菌，酵母，真菌，病毒及其组合的生长。 本发明还公开了通过局部施用治疗组合物来抑制细菌，酵母，真菌，病毒及其组合的生长的治疗方法和治疗系统，所述治疗组合物部分地由分离的芽孢杆菌属物种，孢子或 包含凝结芽孢杆菌菌株培养物的上清液或滤液的凝结芽孢杆菌的细胞外产物。 此外，本发明还公开了抑制细菌，酵母，真菌，病毒及其组合的生长的组合物，治疗方法和治疗系统，所述组合物包含嗜热假单胞菌（Pseudomonas lindbergii）的细胞外产物，其包含培养物的上清液或滤液 所述假丝酵母菌（Lseudomonas lindbergii）菌株。

公开(公告)号：US20080193429A1

公开(公告)日：2008-08-14

申请号：US12148200

申请日：2008-04-17

申请人： Sean Farmer ,  Robert J. Mikhail

发明人： Sean Farmer ,  Robert J. Mikhail

IPC分类号： A61K35/74 ,  A61K35/00 ,  A61P1/00

CPC分类号： C12N1/20 ,  A61K35/742 ,  A61K45/06 ,  Y02A50/469 ,  Y02A50/473

摘要： Compositions including a non-pathogenic lactic acid-producing bacteria, such as a Bacillus species, spores or an extracellular product of B. coagulans, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome (SIDS) are also disclosed.

摘要翻译： 描述了包含非致病性乳酸生产细菌的组合物，例如芽孢杆菌属物种，芽孢或B.凝结芽孢杆菌的细胞外产物，其被配制用于口服给予肠道以抑制细菌性胃肠道感染。 还公开了使用组合物治疗胃肠道感染，特别是婴儿猝死综合征（SIDS）的方法和系统。

公开(公告)号：US20080089963A1

公开(公告)日：2008-04-17

申请号：US11974427

申请日：2007-10-12

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A61K35/74 ,  A61P31/00

CPC分类号： A61Q19/00 ,  A01N63/00 ,  A61K8/73 ,  A61K8/925 ,  A61K8/99 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0046 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/36 ,  A61K35/74 ,  A61K35/742 ,  A61K45/06 ,  A61K47/44 ,  A61L15/36 ,  A61Q19/001 ,  Y02A50/473 ,  Y10S514/887 ,  A61K2300/00

摘要： The present invention discloses compositions derived from an isolated Bacillus species spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions which are comprised, in part, of isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain. In addition, the present invention also discloses compositions, methods of treatment, and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, comprising an extracellular product of Pseudomonas lindbergii comprising a supernatant or filtrate of a culture of said Pseudomonas lindbergii strain.

摘要翻译： 本发明公开了衍生自分离的芽孢杆菌种孢子或凝结芽孢杆菌的细胞外产物的组合物，其包含适于局部施用于哺乳动物皮肤或粘膜的所述凝结芽孢杆菌菌株的培养物的上清液或滤液，其为 用于抑制细菌，酵母，真菌，病毒及其组合的生长。 本发明还公开了通过局部施用治疗组合物来抑制细菌，酵母，真菌，病毒及其组合的生长的治疗方法和治疗系统，所述治疗组合物部分地由分离的芽孢杆菌属物种，孢子或 包含凝结芽孢杆菌菌株培养物的上清液或滤液的凝结芽孢杆菌的细胞外产物。 此外，本发明还公开了抑制细菌，酵母，真菌，病毒及其组合的生长的组合物，治疗方法和治疗系统，所述组合物包含嗜热假单胞菌（Pseudomonas lindbergii）的细胞外产物，其包含培养物的上清液或滤液 所述假丝酵母菌（Lseudomonas lindbergii）菌株。

公开(公告)号：US20060147544A1

公开(公告)日：2006-07-06

申请号：US11376069

申请日：2006-03-14

申请人： Sean Farmer

发明人： Sean Farmer

IPC分类号： A61K35/12 ,  A61K31/7034 ,  A61K31/496 ,  A61K31/63

CPC分类号： A61K31/496 ,  A61K9/0014 ,  A61K9/0034 ,  A61K31/63 ,  A61K31/7034 ,  A61K35/74 ,  A61K35/742 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K47/44 ,  Y02A50/473 ,  Y10S514/887 ,  A61K2300/00

摘要： An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.